Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
暂无分享,去创建一个
M. Andreeff | S. Colla | G. Garcia-Manero | Xuelin Huang | T. Kadia | F. Ravandi | Koichi Takahashi | E. Jabbour | R. Kanagal-Shamanna | N. Short | W. Qiao | L. Masarová | Y. Alvarado | M. Ohanian | G. Montalban-Bravo | I. Ganan-Gomez | H. Kantarjian | K. Chien | M. Yilmaz | A. Bazinet | Deborah McCue | F. Darbaniyan | Bailey Mirabella